AI in Pathology Market - Global Forecast to 2029
商品番号 : SMB-39671
| 出版社 | MarketsandMarkets |
| 出版年月 | 2024年11月 |
| ページ数 | 292 |
| 図表数 | 316 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The global AI in Pathology market is expected to reach USD 169.8 million by 2029 from USD 82.8 million in 2024 at a high CAGR of 15.4% during the forecast period.
世界の病理AI市場は、予測期間中に15.4％という高いCAGRで、2024年の8,280万米ドルから2029年までに1億6,980万米ドルに達すると予想されています。
AI in pathology refers to the healthcare industry’s sector which comprises of development, deployment, and utilization of Artificial Intelligence (AI) designed for pathology applications specifically. Clinical data, genomic information, and disease progression can be analysed by using these AI models. These AI models assist in personalized treatment planning, identifying high-risk patients, and optimizing healthcare resource allocation. The AI helps and assists pathologists in extracting relevant information and analyzing images with the use of advanced AI algorithms, computer vision, and machine learning.
“The drug discovery segment accounted for the largest share in 2023, by use case.”
In 2023, the drug discovery segment held the largest share of the AI in pathology market. The major factor behind this is the high demand for efficient and cost-effective drugs, as AI in pathology helps in accelerating the drug discovery process by automating the data analytics and identifying potential drug faster. In addition, the advancements in high throughput screenings imaging technologies and utilization of AI in toxicology testing for illicit drugs also act as a driving force for this market. Furthermore, the reduced time and costs play a very vital role as traditional methods are very time consuming and expensive as well, the introduction of AI in pathology helps in streamlining the process by enabling faster insights and decision making. Which in tun makes the process more efficient and cost effective, these all factors combined act as a catalyst for the growth of this market.
“Pharmaceutical and biopharmaceutical companies is the fastest growing end-user segment in the AI in pathology market.”
The pharmaceutical and biopharmaceutical companies segment is projected to witness the highest growth rate during the forecast period. The growing collaboration between pharmaceutical companies and AI providers fuels rapid adoption of AI, also the companies are heavily investing in AI tools to stay competitive in drug development and innovation. As AI helps in fast tracking and streamlining the processes for drug discovery by analysing large datasets, identifying patterns in tissue samples, and predicting treatment responses, which reduces the time consumption and makes it cost effective, leading to faster innovations. The biopharmaceutical companies rely on AI-based digital pathology for majorly development of individualized medicine, as AI powered pathology aids the development of personalised medicine by providing detailed insights into individual portfolio.
“North America accounted for the largest share in 2023, in AI in pathology market.”
In 2023, the North American region held the largest market share in the AI in pathology market due to several factors. The first and foremost being the high adoption of AI technology and strong investment in research and development driving the market growth. For instance, companies like Koninklijke Philips N.V. in 2023, invested nearly USD 895 million in R&D for diagnosis and treatment. On the other hand, the advanced healthcare infrastructre plays a very vital role in this market as there’s a need of high tech machinery such as advanced microscopes and scanners. Morover, the large patient pool and data availability contributes in creating a large database, which can be further used to train the AI for greater accuracy and efficiency. This increasing focus on technoology, patient safety, and quality improvement, combined with technological advancements in medical devices, continues to drive the adoption of AI in pathology market in North America.
The break-down of primary participants is as mentioned below:
- By Company Type – Tier 1: 55%, Tier 2: 25%, and Tier 3: 20%
- By Designation – C-level: 50%, Director-level: 30%, and Others: 20%
- By Region – North America: 40%, Europe: 35%, Asia Pacific: 20%, RoW: 5%
Key Players in the AI in pathology Market
The key players functioning in the AI in pathology market include Koninklijke Philips N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (US), Akoya Biosciences, Inc. (US), Aiforia Technologies Plc (Finland), Indica Labs Inc. (US), OptraScan (US), Ibex Medical Analytics Ltd. (Israel), Mindpeak GmbH (Germany), Tribun Health (France), Techcyte, Inc. (US), Deep Bio Inc. (Korea), Lumea Inc. (US), Visiopharm (Denmark), aetherAI (Taiwan), Aiosyn (Netherlands), Paige AI, Inc. (US), Proscia Inc. (US), PathAI, Inc. (US), Tempus Labs, Inc. (US), Konfoong Biotech International Co., Ltd. (China), DoMore Diagnostics AS (Norway), Verily Life Sciences, LLC (US), deepPath (US), and 4D Path Inc (US).
Research Coverage:
The report analyses the AI in pathology market. It aims to estimate the market size and future growth potential of various market segments based on by offerings, neural networks, use-case, end-user, by functions and region. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will enrich established firms and new entrants/smaller firms to gauge the market’s pulse, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights on:
Analysis of key drivers (Rising strategic collaborations among market players, integration of AI in multiplex imaging, Rising cases of misdiagnoses, AI-augmented telepathology broadening access to specialized pathology services, and technological advancements in deep learning), restraints (High cost of digital pathology systems, the scarcity of AI expertise and unclear regulatory guidelines for medical software, and lack of interoperability with legacy systems), opportunities (Growing demand for personalized medicine, integration of multi-omics data, and predictive analytics for disease Progression) challenges (Lack of sufficient data to train AI algorithms, data privacy, and ethical concerns, interpretability of AI models) influencing the growth of the AI in pathology market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the AI in pathology market.
- Market Development: Comprehensive information on the lucrative emerging markets, offering, neural networks, functions, use-case, end-user, and region.
- Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the AI in pathology market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the AI in pathology market like Koninklijke Philips N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (US).
Table of Contents
1 INTRODUCTION 26
1.1 STUDY OBJECTIVES 26
1.2 MARKET DEFINITION 26
1.3 MARKET SCOPE 27
1.3.1 MARKETS COVERED 27
1.3.2 INCLUSIONS & EXCLUSIONS 28
1.3.3 YEARS CONSIDERED 28
1.3.4 CURRENCY CONSIDERED 29
1.4 MARKET STAKEHOLDERS 29
1.5 SUMMARY OF CHANGES 30
2 RESEARCH METHODOLOGY 31
2.1 RESEARCH DATA 31
2.1.1 SECONDARY DATA 32
2.1.1.1 Key data from secondary sources 33
2.1.2 PRIMARY DATA 33
2.1.2.1 Key industry insights 35
2.2 MARKET SIZE ESTIMATION 36
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 41
2.4 STUDY ASSUMPTIONS 42
2.5 RESEARCH LIMITATIONS 42
2.5.1 METHODOLOGY-RELATED LIMITATIONS 42
2.5.2 SCOPE-RELATED LIMITATIONS 43
2.6 RISK ASSESSMENT 43
3 EXECUTIVE SUMMARY 44
4 PREMIUM INSIGHTS 48
4.1 AI IN PATHOLOGY MARKET OVERVIEW 48
4.2 AI IN PATHOLOGY MARKET: REGIONAL MIX 49
4.3 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER & COUNTRY 50
4.4 GEOGRAPHIC GROWTH OPPORTUNITIES 51
5 MARKET OVERVIEW 52
5.1 INTRODUCTION 52
5.2 MARKET DYNAMICS 52
5.2.1 DRIVERS 53
5.2.1.1 Development of CNNs and advanced AI models 53
5.2.1.2 Integration of AI into multiplex imaging 53
5.2.1.3 Increasing cases of misdiagnoses in patients 54
5.2.1.4 Benefits of AI-augmented telepathology 54
5.2.1.5 Advancements in deep learning & image processing 55
5.2.2 RESTRAINTS 55
5.2.2.1 High cost of digital pathology systems 55
5.2.2.2 Limited AI expertise and varied regulatory guidelines for medical software 56
5.2.2.3 Inadequate interoperability issues with legacy systems 56
5.2.3 OPPORTUNITIES 57
5.2.3.1 Increasing demand for personalized medicine 57
5.2.3.2 Integration of multi-omics data 57
5.2.3.3 Predictive analytics for disease progression 58
5.2.4 CHALLENGES 58
5.2.4.1 Insufficient data for AI algorithms 58
5.2.4.2 Data privacy & ethical concerns 58
5.2.4.3 Challenges associated with interpretability of AI models 59
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 60
5.4 INDUSTRY TRENDS 60
5.4.1 EVOLUTION OF AI IN PATHOLOGY 60
5.5 ECOSYSTEM ANALYSIS 61
5.6 VALUE CHAIN ANALYSIS 62
5.7 TECHNOLOGY ANALYSIS 64
5.7.1 KEY TECHNOLOGIES 64
5.7.1.1 Machine learning and artificial intelligence 64
5.7.1.2 Computer vision 64
5.7.2 COMPLEMENTARY TECHNOLOGIES 64
5.7.2.1 Cloud computing 64
5.7.3 ADJACENT TECHNOLOGIES 65
5.7.3.1 Telepathology 65
5.8 REGULATORY ANALYSIS 65
5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 65
5.8.2 REGULATORY LANDSCAPE 66
5.8.2.1 North America 66
5.8.2.1.1 US 66
5.8.2.1.2 Canada 67
5.8.2.2 Europe 67
5.8.2.3 Asia Pacific 69
5.8.2.3.1 Japan 69
5.8.2.3.2 China 69
5.9 PRICING ANALYSIS 70
5.9.1 INDICATIVE PRICING ANALYSIS, BY OFFERING 70
5.9.2 AVERAGE SELLING PRICE TREND, BY REGION 71
5.10 PORTER’S FIVE FORCES ANALYSIS 71
5.10.1 THREAT OF NEW ENTRANTS 72
5.10.2 THREAT OF SUBSTITUTES 72
5.10.3 BARGAINING POWER OF SUPPLIERS 72
5.10.4 BARGAINING POWER OF BUYERS 72
5.10.5 INTENSITY OF COMPETITIVE RIVALRY 73
5.11 PATENT ANALYSIS 73
5.11.1 PATENT PUBLICATION TRENDS FOR AI IN PATHOLOGY SOLUTIONS 73
5.11.2 JURISDICTION & TOP APPLICANT ANALYSIS 74
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 75
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 75
5.12.2 BUYING CRITERIA 76
5.13 END-USER ANALYSIS 77
5.13.1 UNMET NEEDS OF END USERS 77
5.13.2 END-USER EXPECTATIONS 77
5.14 KEY CONFERENCES AND EVENTS, 2024–2025 78
5.15 CASE STUDY ANALYSIS 79
5.15.1 CASE STUDY 1: PATHAI USES PYTORCH TO IMPROVE PATIENT OUTCOMES WITH AI-POWERED PATHOLOGY 79
5.15.2 CASE STUDY 2: COMBATING CERVICAL CANCER WITH AI 79
5.16 INVESTMENT & FUNDING SCENARIO 79
5.17 AI IN PATHOLOGY MARKET: BUSINESS MODELS 80
5.18 IMPACT OF AI/GEN AI ON AI IN PATHOLOGY MARKET 81
5.18.1 KEY USE CASES 82
5.18.2 CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION 82
5.18.2.1 Case Study: Accelerated biomarker discovery and clinical trial optimization 82
5.18.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 83
5.18.3.1 Drug discovery & development market 83
5.18.3.2 Medical imaging & diagnostics market 83
5.18.4 USERS READINESS AND IMPACT ASSESSMENT 84
5.18.4.1 User readiness 84
5.18.4.1.1 Pharmaceutical companies 84
5.18.4.1.2 Biopharmaceutical companies 84
5.18.4.2 Impact assessment 84
5.18.4.2.1 User A: Pharmaceutical companies 84
5.18.4.2.1.1 Implementation 84
5.18.4.2.1.2 Impact 85
5.18.4.2.2 User B: Biopharmaceutical companies 85
5.18.4.2.2.1 Implementation 85
5.18.4.2.2.2 Impact 85
5.19 TRADE ANALYSIS 86
5.19.1 IMPORT DATA 86
5.19.2 EXPORT DATA 87
6 AI IN PATHOLOGY MARKET, BY OFFERING 88
6.1 INTRODUCTION 89
6.2 END-TO-END SOLUTIONS 91
6.2.1 INCREASING DEMAND FOR INTEGRATED WORKFLOWS IN HEALTHCARE MODELS TO DRIVE MARKET 91
6.3 NICHE POINT SOLUTIONS 92
6.3.1 GROWING FOCUS ON PRECISION MEDICINE AND TARGETED THERAPY RESEARCH TO PROPEL MARKET 92
6.4 TECHNOLOGY 93
6.4.1 RISING NEED FOR ADVANCED DATA MANAGEMENT SOLUTIONS
TO FUEL UPTAKE 93
6.5 HARDWARE 94
6.6 MICROSCOPES 95
6.6.1 AUTOMATED ANALYSIS OF TISSUE SAMPLES FOR EFFECTIVE CONCLUSIONS TO FUEL UPTAKE 95
6.7 SCANNERS 96
6.7.1 IMPROVEMENTS IN IMAGE QUALITY AND PRECISION DIAGNOSTICS TO BOOST DEMAND 96
6.8 STORAGE SYSTEMS 98
6.8.1 ABILITY TO PROVIDE STRUCTURED MODELS OF HIGH-RESOLUTION IMAGES TO SUPPORT MARKET GROWTH 98
7 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK 100
7.1 INTRODUCTION 101
7.2 CONVOLUTIONAL NEURAL NETWORKS (CNNS) 101
7.2.1 ABILITY TO PROVIDE HIGH-QUALITY IMAGE RECOGNITION AND OBJECTION DETECTION TO PROPEL MARKET 101
7.3 GENERATIVE ADVERSARIAL NETWORKS (GANS) 103
7.3.1 DESIGNED FOR GENERATION OF ACCURATE SYNTHETIC PATHOLOGY IMAGES TO DRIVE MARKET 103
7.4 RECURRENT NEURAL NETWORKS (RNNS) 104
7.4.1 ANALYSIS OF SEQUENTIAL DATA AND TIME-DEPENDENT PATTERNS TO FUEL UPTAKE 104
7.5 OTHER NEURAL NETWORKS 106
8 AI IN PATHOLOGY MARKET, BY FUNCTION 107
8.1 INTRODUCTION 108
8.2 IMAGE ANALYSIS 109
8.2.1 DETECTION OF CELLULAR ANOMALIES AND DISEASE MARKERS TO FUEL UPTAKE 109
8.3 DIAGNOSTICS 110
8.3.1 RAPID PROCESSION OF AUTOMATED SAMPLES TO DRIVE MARKET 110
8.4 WORKFLOW MANAGEMENT 111
8.4.1 OPTIMIZATION OF LAB RESOURCES FOR HIGH-THROUGHPUT RESULTS TO FUEL UPTAKE 111
8.5 DATA MANAGEMENT 112
8.5.1 ADVANCEMENTS IN DATA INTEGRATION & PROCESSING TO BOOST DEMAND 112
8.6 PREDICTIVE ANALYTICS 113
8.6.1 GROWING FOCUS ON EARLY DISEASE DIAGNOSIS TO DRIVE MARKET 113
8.7 CDSS 114
8.7.1 PROVISION OF REAL-TIME INSIGHTS TO FUEL MARKET 114
8.8 AUTOMATED REPORT GENERATION 115
8.8.1 INCREASING DEMAND FOR QUALITY CONTROL TO DRIVE MARKET 115
8.9 QUALITY ASSURANCE TOOLS 116
8.9.1 RISING REGULATORY DEMANDS TO ACCELERATE DEMAND FOR QUALITY ASSURANCE TOOLS 116
9 AI IN PATHOLOGY MARKET, BY USE CASE 117
9.1 INTRODUCTION 118
9.2 DRUG DISCOVERY 118
9.2.1 TARGET IDENTIFICATION & SELECTION 121
9.2.1.1 Analysis of molecular & histological data for biomarker discovery to fuel market 121
9.2.2 TARGET VALIDATION 122
9.2.2.1 Increasing demand for precision medicine to drive market 122
9.2.3 HIT IDENTIFICATION & PRIORITIZATION 123
9.2.3.1 Growing requirement for rapid analysis and cost efficiency to fuel uptake 123
9.2.4 HIT-TO-LEAD IDENTIFICATION 124
9.2.4.1 Advancements in ML to support market growth 124
9.2.5 LEAD OPTIMIZATION 125
9.2.5.1 Growing focus on therapeutic efficacy to propel market 125
9.2.6 CANDIDATE SELECTION & VALIDATION 126
9.2.6.1 Critical requirement for regulatory approvals to drive market 126
9.3 DISEASE DIAGNOSIS & PROGNOSIS 127
9.3.1 INCREASING INCIDENCE OF CHRONIC DISEASES TO FUEL MARKET 127
9.4 CLINICAL WORKFLOW 128
9.4.1 STRUCTURED AUTOMATION OF EXTENSIVE VOLUME DATA TO DRIVE MARKET 128
9.5 TRAINING & EDUCATION 129
9.5.1 UTILIZATION OF DIGITAL PATHOLOGY SYSTEMS IN ACADEMIC INSTITUTES TO SUPPORT MARKET GROWTH 129
10 AI IN PATHOLOGY MARKET, BY END USER 131
10.1 INTRODUCTION 132
10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 132
10.2.1 GROWING FOCUS ON TOXICOLOGY TESTING TO PROPEL MARKET 132
10.3 HOSPITALS & REFERENCE LABORATORIES 133
10.3.1 INCREASING UPTAKE OF INFECTIOUS DISEASE DIAGNOSIS TO DRIVE MARKET 133
10.4 ACADEMIC & RESEARCH INSTITUTES 135
10.4.1 INCREASING INVESTMENTS IN LIFE SCIENCES RESEARCH TO SUPPORT MARKET GROWTH 135
11 AI IN PATHOLOGY MARKET, BY REGION 136
11.1 INTRODUCTION 137
11.2 NORTH AMERICA 137
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 137
11.2.2 US 141
11.2.2.1 High healthcare expenditure and improvements in cloud computing platforms to propel market 141
11.2.3 CANADA 145
11.2.3.1 Increasing adoption of deep learning for advanced healthcare diagnostics to drive market 145
11.3 EUROPE 147
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 148
11.3.2 UK 151
11.3.2.1 Increasing focus on drug discovery & development to boost demand 151
11.3.3 GERMANY 153
11.3.3.1 Availability of funding for AI initiatives to fuel uptake 153
11.3.4 FRANCE 156
11.3.4.1 Increasing adoption of big data in healthcare computing to fuel uptake 156
11.3.5 ITALY 159
11.3.5.1 Digital transformation and innovation in healthcare to support market growth 159
11.3.6 SPAIN 161
11.3.6.1 Workforce shortages to fuel market 161
11.3.7 REST OF EUROPE 164
11.4 ASIA PACIFIC 167
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 167
11.4.2 CHINA 171
11.4.2.1 Increasing incidence of infectious & chronic diseases to fuel uptake 171
11.4.3 JAPAN 174
11.4.3.1 Advanced healthcare infrastructure to propel market 174
11.4.4 INDIA 177
11.4.4.1 Growing focus on healthcare digitization to boost demand 177
11.4.5 REST OF ASIA PACIFIC 180
11.5 LATIN AMERICA 183
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 183
11.5.2 BRAZIL 186
11.5.2.1 Strategic investments for AI adoption to support market growth 186
11.5.3 MEXICO 189
11.5.3.1 Growth in pharmaceutical R&D to drive market 189
11.5.4 REST OF LATIN AMERICA 191
11.6 MIDDLE EAST & AFRICA 194
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 194
11.6.2 GCC COUNTRIES 197
11.6.2.1 Increasing investments in expansion of technological expertise to support market growth 197
11.6.3 REST OF MIDDLE EAST & AFRICA 200
12 COMPETITIVE LANDSCAPE 204
12.1 INTRODUCTION 204
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 204
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AI IN PATHOLOGY MARKET 205
12.3 REVENUE ANALYSIS, 2019−2023 207
12.4 MARKET SHARE ANALYSIS, 2023 207
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 210
12.5.1 STARS 210
12.5.2 EMERGING LEADERS 210
12.5.3 PERVASIVE PLAYERS 210
12.5.4 PARTICIPANTS 210
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 212
12.5.5.1 Company footprint 212
12.5.5.2 Offering footprint 213
12.5.5.3 Use-case footprint 214
12.5.5.4 End-user footprint 215
12.5.5.5 Region footprint 216
12.6 COMPANY EVALUATION MATRIX: STARTUPS /SMES, 2023 217
12.6.1 PROGRESSIVE COMPANIES 217
12.6.2 RESPONSIVE COMPANIES 217
12.6.3 DYNAMIC COMPANIES 217
12.6.4 STARTING BLOCKS 217
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 219
12.7 COMPANY VALUATION & FINANCIAL METRICS 220
12.7.1 COMPANY VALUATION 220
12.7.2 FINANCIAL METRICS 220
12.7.3 BRAND/SOFTWARE COMPARISON ANALYSIS 221
12.8 COMPETITIVE SCENARIO 222
12.8.1 PRODUCT/SERVICE LAUNCHES & APPROVALS 222
12.8.2 DEALS 223
12.8.3 OTHER DEVELOPMENTS 224
13 COMPANY PROFILES 225
13.1 KEY PLAYERS 225
13.1.1 KONINKLIJKE PHILIPS N.V. 225
13.1.1.1 Business overview 225
13.1.1.2 Products/Services offered 226
13.1.1.3 MnM view 227
13.1.1.3.1 Key strengths 227
13.1.1.3.2 Strategic choices 227
13.1.1.3.3 Weaknesses & competitive threats 227
13.1.2 F. HOFFMANN-LA ROCHE LTD. 228
13.1.2.1 Business overview 228
13.1.2.2 Products/Services offered 229
13.1.2.3 Recent developments 230
13.1.2.3.1 Product/Service launches 230
13.1.2.3.2 Deals 231
13.1.2.4 MnM view 231
13.1.2.4.1 Key strengths 231
13.1.2.4.2 Strategic choices 231
13.1.2.4.3 Weaknesses & competitive threats 231
13.1.3 HOLOGIC, INC. 232
13.1.3.1 Business overview 232
13.1.3.2 Products/Services offered 233
13.1.3.3 Recent developments 234
13.1.3.3.1 Product/Service approvals 234
13.1.3.4 MnM view 234
13.1.3.4.1 Key strengths 234
13.1.3.4.2 Strategic choices 234
13.1.3.4.3 Weaknesses & competitive threats 234
13.1.4 AKOYA BIOSCIENCES, INC. 235
13.1.4.1 Business overview 235
13.1.4.2 Products/Services offered 237
13.1.4.3 Recent developments 237
13.1.4.3.1 Deals 237
13.1.4.4 MnM view 238
13.1.4.4.1 Key strengths 238
13.1.4.4.2 Strategic choices 238
13.1.4.4.3 Weaknesses & competitive threats 238
13.1.5 AIFORIA TECHNOLOGIES PLC 239
13.1.5.1 Business overview 239
13.1.5.2 Products/Services offered 240
13.1.5.3 Recent developments 241
13.1.5.3.1 Deals 241
13.1.5.4 MnM view 241
13.1.5.4.1 Key strengths 241
13.1.5.4.2 Strategic choices 241
13.1.5.4.3 Weaknesses & competitive threats 241
13.1.6 INDICA LABS INC. 242
13.1.6.1 Business overview 242
13.1.6.2 Products/Services offered 242
13.1.6.3 Recent developments 243
13.1.6.3.1 Product/Service launches & approvals 243
13.1.6.3.2 Deals 244
13.1.6.3.3 Expansions 245
13.1.7 OPTRASCAN 246
13.1.7.1 Business overview 246
13.1.7.2 Products/Services offered 246
13.1.7.3 Recent developments 247
13.1.7.3.1 Other developments 247
13.1.8 IBEX MEDICAL ANALYTICS LTD. 248
13.1.8.1 Business overview 248
13.1.8.2 Products/Services offered 248
13.1.8.3 Recent developments 249
13.1.8.3.1 Product/Service launches & approvals 249
13.1.8.3.2 Deals 250
13.1.9 MINDPEAK GMBH 252
13.1.9.1 Business overview 252
13.1.9.2 Products/Services offered 252
13.1.9.3 Recent developments 253
13.1.9.3.1 Product/Service approvals 253
13.1.9.3.2 Deals 253
13.1.9.3.3 Other developments 253
13.1.10 TRIBUN HEALTH 254
13.1.10.1 Business overview 254
13.1.10.2 Products/Services offered 254
13.1.10.3 Recent developments 255
13.1.10.3.1 Deals 255
13.1.11 TECHCYTE, INC. 256
13.1.11.1 Business overview 256
13.1.11.2 Products/services offered 256
13.1.11.3 Recent developments 257
13.1.11.3.1 Product/Service launches 257
13.1.11.3.2 Deals 257
13.1.11.3.3 Other developments 257
13.1.12 DEEP BIO INC. 258
13.1.12.1 Business overview 258
13.1.12.2 Products/Services offered 258
13.1.12.3 Recent developments 259
13.1.12.3.1 Deals 259
13.1.13 LUMEA INC. 260
13.1.13.1 Business overview 260
13.1.13.2 Products/Services offered 260
13.1.13.3 Recent developments 261
13.1.13.3.1 Deals 261
13.1.14 VISIOPHARM 262
13.1.14.1 Business overview 262
13.1.14.2 Products/Services offered 262
13.1.14.2.1 Recent developments 263
13.1.14.2.2 Product/Service launches 263
13.1.14.2.3 Expansions 263
13.1.15 AETHERAI 265
13.1.15.1 Business overview 265
13.1.15.2 Products/Services offered 265
13.1.15.3 Recent developments 265
13.1.15.3.1 Deals 265
13.1.16 AIOSYN 266
13.1.16.1 Business overview 266
13.1.16.2 Product/Services offered 266
13.1.16.2.1 Product/Service launches 267
13.1.16.3 Recent developments 267
13.1.16.3.1 Deals 267
13.1.16.4 Recent developments 267
13.1.16.4.1 Other developments 267
13.1.17 PAIGE AI, INC. 268
13.1.17.1 Business overview 268
13.1.17.2 Products/Services offered 268
13.1.17.3 Recent developments 269
13.1.17.3.1 Product/Service launches & approvals 269
13.1.17.3.2 Deals 270
13.1.17.3.3 Other developments 270
13.1.18 PROSCIA, INC. 271
13.1.18.1 Business overview 271
13.1.18.2 Products/Services offered 271
13.1.18.3 Recent developments 272
13.1.18.3.1 Product/Service launches & enhancements 272
13.1.18.3.2 Deals 273
13.1.18.3.3 Other developments 273
13.1.19 PATHAI, INC. 274
13.1.19.1 Business overview 274
13.1.19.2 Products/Services offered 274
13.1.19.3 Recent developments 275
13.1.19.3.1 Product/Service launches & approvals 275
13.1.19.3.2 Deals 276
13.1.20 TEMPUS LABS, INC. 277
13.1.20.1 Business overview 277
13.1.20.2 Products/Services offered 277
13.1.20.3 Recent developments 277
13.1.20.3.1 Product/Service launches 277
13.2 OTHER PLAYERS 278
13.2.1 KONFOONG BIOINFORMATION TECH CO., LTD. 278
13.2.2 DOMORE DIAGNOSTICS AS 278
13.2.3 VERILY LIFE SCIENCES, LLC 279
13.2.4 DEEPPATH 279
13.2.5 4D PATH INC. 280
14 APPENDIX 281
14.1 DISCUSSION GUIDE 281
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 288
14.3 CUSTOMIZATION OPTIONS 290
14.4 RELATED REPORTS 290
14.5 AUTHOR DETAILS 291
LIST OF TABLES
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 29
TABLE 2 STUDY ASSUMPTION ANALYSIS 42
TABLE 3 RISK ASSESSMENT ANALYSIS 43
TABLE 4 AI IN PATHOLOGY MARKET: ROLE IN ECOSYSTEM 62
TABLE 5 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 65
TABLE 6 US FDA: MEDICAL DEVICE CLASSIFICATION 66
TABLE 7 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 66
TABLE 8 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 67
TABLE 9 EUROPE: CLASSIFICATION OF IVD DEVICES 68
TABLE 10 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 69
TABLE 11 CHINA: CLASSIFICATION OF MEDICAL DEVICES 70
TABLE 12 INDICATIVE PRICING ANALYSIS, BY OFFERING 70
TABLE 13 AI IN PATHOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS 72
TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AI IN PATHOLOGY PRODUCTS (%) 75
TABLE 15 KEY BUYING CRITERIA FOR AI IN PATHOLOGY PRODUCTS 76
TABLE 16 UNMET NEEDS FOR AI IN PATHOLOGY MARKET 77
TABLE 17 END-USER EXPECTATIONS FOR AI IN PATHOLOGY MARKET 78
TABLE 18 AI IN PATHOLOGY MARKET: LIST OF CONFERENCES AND EVENTS 78
TABLE 19 IMPORT DATA FOR HS CODE 9011, BY COUNTRY, 2020–2022 (USD THOUSAND) 86
TABLE 20 EXPORT DATA FOR HS CODE 9011, BY COUNTRY, 2020–2022 (USD THOUSAND) 87
TABLE 21 AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 89
TABLE 22 AI IN PATHOLOGY MARKET FOR OFFERING, BY COUNTRY,
2022–2029 (USD MILLION) 90
TABLE 23 AI IN PATHOLOGY MARKET FOR END-TO-END SOLUTIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 91
TABLE 24 AI IN PATHOLOGY MARKET FOR NICHE-POINT SOLUTIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 92
TABLE 25 AI IN PATHOLOGY MARKET FOR TECHNOLOGY, BY COUNTRY,
2022–2029 (USD MILLION) 93
TABLE 26 AI IN PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2022–2029 (USD MILLION) 94
TABLE 27 AI IN PATHOLOGY MARKET FOR HARDWARE, BY COUNTRY,
2022–2029 (USD MILLION) 94
TABLE 28 AI IN PATHOLOGY MARKET FOR MICROSCOPES, BY COUNTRY,
2022–2029 (USD MILLION) 96
TABLE 29 AI IN PATHOLOGY MARKET FOR SCANNERS, BY COUNTRY,
2022–2029 (USD MILLION) 97
TABLE 30 AI IN PATHOLOGY MARKET FOR STORAGE SYSTEMS,
BY COUNTRY, 2022–2029 (USD MILLION) 99
TABLE 31 AI IN PATHOLOGY MARKET, BY NEURAL NETWORKS, 2022–2029 (USD MILLION) 101
TABLE 32 AI IN PATHOLOGY MARKET FOR CONVOLUTIONAL NEURAL NETWORKS,
BY COUNTRY, 2022–2029 (USD MILLION) 102
TABLE 33 AI IN PATHOLOGY MARKET FOR GENERATIVE ADVERSARIAL NETWORKS,
BY COUNTRY, 2022–2029 (USD MILLION) 104
TABLE 34 AI IN PATHOLOGY MARKET FOR RECURRENT NEURAL NETWORKS,
BY COUNTRY, 2022–2029 (USD MILLION) 105
TABLE 35 AI IN PATHOLOGY MARKET FOR OTHER NEURAL NETWORKS,
BY COUNTRY, 2022–2029 (USD MILLION) 106
TABLE 36 AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 108
TABLE 37 AI IN PATHOLOGY MARKET FOR IMAGE ANALYSIS, BY COUNTRY,
2022–2029 (USD MILLION) 109
TABLE 38 AI IN PATHOLOGY MARKET FOR DIAGNOSTICS, BY COUNTRY,
2022–2029 (USD MILLION) 110
TABLE 39 AI IN PATHOLOGY MARKET FOR WORKFLOW MANAGEMENT,
BY COUNTRY, 2022–2029 (USD MILLION) 111
TABLE 40 AI IN PATHOLOGY MARKET FOR DATA MANAGEMENT,
BY COUNTRY, 2022–2029 (USD MILLION) 112
TABLE 41 AI IN PATHOLOGY MARKET FOR PREDICTIVE ANALYTICS,
BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 42 AI IN PATHOLOGY MARKET FOR CDSS, BY COUNTRY, 2022–2029 (USD MILLION) 114
TABLE 43 AI IN PATHOLOGY MARKET FOR AUTOMATED REPORT GENERATION,
BY COUNTRY, 2022–2029 (USD MILLION) 115
TABLE 44 AI IN PATHOLOGY MARKET FOR QUALITY ASSURANCE TOOLS,
BY COUNTRY, 2022–2029 (USD MILLION) 116
TABLE 45 AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION) 118
TABLE 46 DRUG DISCOVERY APPLICATIONS FOR AI IN PATHOLOGY 118
TABLE 47 AI IN PATHOLOGY MARKET FOR DRUG DISCOVERY,
BY TYPE, 2022–2029 (USD MILLION) 119
TABLE 48 AI IN PATHOLOGY MARKET FOR DRUG DISCOVERY,
BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 49 AI IN PATHOLOGY MARKET FOR TARGET IDENTIFICATION & SELECTION,
BY COUNTRY, 2022–2029 (USD MILLION) 121
TABLE 50 AI IN PATHOLOGY MARKET FOR TARGET VALIDATION, BY COUNTRY,
2022–2029 (USD MILLION) 122
TABLE 51 AI IN PATHOLOGY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION,
BY COUNTRY, 2022–2029 (USD MILLION) 123
TABLE 52 AI IN PATHOLOGY MARKET FOR HIT-TO-LEAD, BY COUNTRY,
2022–2029 (USD MILLION) 124
TABLE 53 AI IN PATHOLOGY MARKET FOR LEAD OPTIMIZATION,
BY COUNTRY, 2022–2029 (USD MILLION) 125
TABLE 54 AI IN PATHOLOGY MARKET FOR CANDIDATE SELECTION & VALIDATION,
BY COUNTRY, 2022–2029 (USD MILLION) 126
TABLE 55 AI IN PATHOLOGY MARKET FOR DISEASE DIAGNOSIS & PROGNOSIS,
BY COUNTRY, 2022–2029 (USD MILLION) 128
TABLE 56 AI IN PATHOLOGY MARKET FOR CLINICAL WORKFLOW,
BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 57 AI IN PATHOLOGY MARKET FOR TRAINING & EDUCATION,
BY COUNTRY, 2022–2029 (USD MILLION) 130
TABLE 58 AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 132
TABLE 59 AI IN PATHOLOGY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 60 AI IN PATHOLOGY MARKET FOR HOSPITALS & REFERENCE LABORATORIES,
BY COUNTRY, 2022–2029 (USD MILLION) 134
TABLE 61 AI IN PATHOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY COUNTRY, 2022–2029 (USD MILLION) 135
TABLE 62 AI IN PATHOLOGY MARKET, BY REGION, 2022–2029 (USD MILLION) 137
TABLE 63 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 139
TABLE 64 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 139
TABLE 65 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 140
TABLE 66 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2022–2029 (USD MILLION) 140
TABLE 67 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE,
2022–2029 (USD MILLION) 141
TABLE 68 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 141
TABLE 69 US: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 143
TABLE 70 US: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 143
TABLE 71 US: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2022–2029 (USD MILLION) 144
TABLE 72 US: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION) 144
TABLE 73 US: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 144
TABLE 74 CANADA: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 145
TABLE 75 CANADA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 146
TABLE 76 CANADA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2022–2029 (USD MILLION) 146
TABLE 77 CANADA: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION) 147
TABLE 78 CANADA: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 147
TABLE 79 EUROPE: AI IN PATHOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 148
TABLE 80 EUROPE: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 149
TABLE 81 EUROPE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 149
TABLE 82 EUROPE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2022–2029 (USD MILLION) 150
TABLE 83 EUROPE: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION) 150
TABLE 84 EUROPE: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 150
TABLE 85 UK: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 151
TABLE 86 UK: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 152
TABLE 87 UK: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2022–2029 (USD MILLION) 152
TABLE 88 UK: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION) 153
TABLE 89 UK: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 153
TABLE 90 GERMANY: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 154
TABLE 91 GERMANY: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 154
TABLE 92 GERMANY: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2022–2029 (USD MILLION) 155
TABLE 93 GERMANY: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION) 155
TABLE 94 GERMANY: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 155
TABLE 95 FRANCE: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 156
TABLE 96 FRANCE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 157
TABLE 97 FRANCE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2022–2029 (USD MILLION) 157
TABLE 98 FRANCE: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION) 158
TABLE 99 FRANCE: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 158
TABLE 100 ITALY: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 159
TABLE 101 ITALY: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 160
TABLE 102 ITALY: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2022–2029 (USD MILLION) 160
TABLE 103 ITALY: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION) 161
TABLE 104 ITALY: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 161
TABLE 105 SPAIN: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 162
TABLE 106 SPAIN: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 162
TABLE 107 SPAIN: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2022–2029 (USD MILLION) 163
TABLE 108 SPAIN: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION) 163
TABLE 109 SPAIN: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 163
TABLE 110 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 165
TABLE 111 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 165
TABLE 112 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2022–2029 (USD MILLION) 166
TABLE 113 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY USE CASE,
2022–2029 (USD MILLION) 166
TABLE 114 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 166
TABLE 115 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 169
TABLE 116 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 169
TABLE 117 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 170
TABLE 118 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2022–2029 (USD MILLION) 170
TABLE 119 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY USE CASE,
2022–2029 (USD MILLION) 171
TABLE 120 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 171
TABLE 121 CHINA: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 172
TABLE 122 CHINA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 172
TABLE 123 CHINA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2022–2029 (USD MILLION) 173
TABLE 124 CHINA: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION) 173
TABLE 125 CHINA: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 173
TABLE 126 JAPAN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 174
TABLE 127 JAPAN: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 175
TABLE 128 JAPAN: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 175
TABLE 129 JAPAN: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2022–2029 (USD MILLION) 176
TABLE 130 JAPAN: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION) 176
TABLE 131 JAPAN: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 176
TABLE 132 INDIA: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 177
TABLE 133 INDIA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 178
TABLE 134 INDIA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2022–2029 (USD MILLION) 178
TABLE 135 INDIA: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION) 179
TABLE 136 INDIA: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 179
TABLE 137 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET,
BY OFFERING, 2022–2029 (USD MILLION) 180
TABLE 138 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET,
BY FUNCTION, 2022–2029 (USD MILLION) 181
TABLE 139 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET,
BY NEURAL NETWORK, 2022–2029 (USD MILLION) 181
TABLE 140 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET,
BY USE CASE, 2022–2029 (USD MILLION) 182
TABLE 141 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET,
BY END USER, 2022–2029 (USD MILLION) 182
TABLE 142 LATIN AMERICA: AI IN PATHOLOGY MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 184
TABLE 143 LATIN AMERICA: AI IN PATHOLOGY MARKET,
BY OFFERING, 2022–2029 (USD MILLION) 184
TABLE 144 LATIN AMERICA: AI IN PATHOLOGY MARKET,
BY FUNCTION, 2022–2029 (USD MILLION) 185
TABLE 145 LATIN AMERICA: AI IN PATHOLOGY MARKET,
BY NEURAL NETWORK, 2022–2029 (USD MILLION) 185
TABLE 146 LATIN AMERICA: AI IN PATHOLOGY MARKET,
BY USE CASE, 2022–2029 (USD MILLION) 186
TABLE 147 LATIN AMERICA: AI IN PATHOLOGY MARKET,
BY END USER, 2022–2029 (USD MILLION) 186
TABLE 148 BRAZIL: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 187
TABLE 149 BRAZIL: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 187
TABLE 150 BRAZIL: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2022–2029 (USD MILLION) 188
TABLE 151 BRAZIL: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION) 188
TABLE 152 BRAZIL: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 188
TABLE 153 MEXICO: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 189
TABLE 154 MEXICO: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 190
TABLE 155 MEXICO: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2022–2029 (USD MILLION) 190
TABLE 156 MEXICO: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION) 191
TABLE 157 MEXICO: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 191
TABLE 158 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET,
BY OFFERING, 2022–2029 (USD MILLION) 192
TABLE 159 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET,
BY FUNCTION, 2022–2029 (USD MILLION) 192
TABLE 160 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET,
BY NEURAL NETWORK, 2022–2029 (USD MILLION) 193
TABLE 161 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET,
BY USE CASE, 2022–2029 (USD MILLION) 193
TABLE 162 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET,
BY END USER, 2022–2029 (USD MILLION) 194
TABLE 163 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET,
BY REGION, 2022–2029 (USD MILLION) 195
TABLE 164 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET,
BY OFFERING, 2022–2029 (USD MILLION) 195
TABLE 165 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET,
BY FUNCTION, 2022–2029 (USD MILLION) 196
TABLE 166 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET,
BY NEURAL NETWORK, 2022–2029 (USD MILLION) 196
TABLE 167 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET,
BY USE CASE, 2022–2029 (USD MILLION) 197
TABLE 168 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET,
BY END USER, 2022–2029 (USD MILLION) 197
TABLE 169 GCC COUNTRIES: AI IN PATHOLOGY MARKET,
BY OFFERING, 2022–2029 (USD MILLION) 198
TABLE 170 GCC COUNTRIES: AI IN PATHOLOGY MARKET,
BY FUNCTION, 2022–2029 (USD MILLION) 199
TABLE 171 GCC COUNTRIES: AI IN PATHOLOGY MARKET,
BY NEURAL NETWORK, 2022–2029 (USD MILLION) 199
TABLE 172 GCC COUNTRIES: AI IN PATHOLOGY MARKET,
BY USE CASE, 2022–2029 (USD MILLION) 200
TABLE 173 GCC COUNTRIES: AI IN PATHOLOGY MARKET,
BY END USER, 2022–2029 (USD MILLION) 200
TABLE 174 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET,
BY OFFERING, 2022–2029 (USD MILLION) 201
TABLE 175 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET,
BY FUNCTION, 2022–2029 (USD MILLION) 201
TABLE 176 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET,
BY NEURAL NETWORK, 2022–2029 (USD MILLION) 202
TABLE 177 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET,
BY USE CASE, 2022–2029 (USD MILLION) 202
TABLE 178 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET,
BY END USER, 2022–2029 (USD MILLION) 203
TABLE 179 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES 205
TABLE 180 AI IN PATHOLOGY MARKET: DEGREE OF COMPETITION 209
TABLE 181 OFFERING FOOTPRINT ANALYSIS 213
TABLE 182 USE-CASE FOOTPRINT ANALYSIS 214
TABLE 183 END-USER FOOTPRINT ANALYSIS 215
TABLE 184 REGION FOOTPRINT ANALYSIS 216
TABLE 185 AI IN PATHOLOGY MARKET: DETAILED LIST OF KEY START-UPS/SMES 219
TABLE 186 AI IN PATHOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS 219
TABLE 187 AI IN PATHOLOGY MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–OCTOBER 2024 222
TABLE 188 AI IN PATHOLOGY MARKET: DEALS, JANUARY 2021–OCTOBER 2024 223
TABLE 189 AI IN PATHOLOGY MARKET: OTHER DEVELOPMENTS, 2021–2024 224
TABLE 190 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 225
TABLE 191 KONINKLIJKE PHILIPS N.V.: PRODUCTS/SERVICES OFFERED 226
TABLE 192 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 228
TABLE 193 F. HOFFMANN LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED 229
TABLE 194 F. HOFFMANN-LA ROCHE LTD.: PRODUCT/SERVICE LAUNCHES,
JANUARY 2021−OCTOBER 2024 230
TABLE 195 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021−OCTOBER 2024 231
TABLE 196 HOLOGIC, INC.: COMPANY OVERVIEW 232
TABLE 197 HOLOGIC, INC.: PRODUCTS/SERVICES OFFERED 233
TABLE 198 HOLOGIC, INC.: PRODUCT/SERVICE APPROVALS, JANUARY 2021−OCTOBER 2024 234
TABLE 199 AKOYA BIOSCIENCES, INC.: COMPANY OVERVIEW 235
TABLE 200 AKOYA BIOSCIENCES, INC.: PRODUCT/SERVICES OFFERED 237
TABLE 201 AKOYA BIOSCIENCES INC.: DEALS, JANUARY 2021−OCTOBER 2024 237
TABLE 202 AIFORIA TECHNOLOGIES PLC: COMPANY OVERVIEW 239
TABLE 203 AIFORIA TECHNOLOGIES PLC: PRODUCT/SERVICES OFFERED 240
TABLE 204 AIFORIA TECHNOLOGIES PLC: DEALS, JANUARY 2021−OCTOBER 2024 241
TABLE 205 INDICA LABS INC.: COMPANY OVERVIEW 242
TABLE 206 INDICA LABS INC.: PRODUCTS/SERVICES OFFERED 242
TABLE 207 INDICA LABS INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS,
JANUARY 2021−OCTOBER 2024 243
TABLE 208 INDICA LABS INC.: DEALS, JANUARY 2021−OCTOBER 2024 244
TABLE 209 INDICA LABS INC.: EXPANSIONS, JANUARY 2021–OCTOBER 2024 245
TABLE 210 OPTRASCAN: COMPANY OVERVIEW 246
TABLE 211 OPTRASCAN: PRODUCTS/SERVICES OFFERED 246
TABLE 212 OPTRASCAN: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024 247
TABLE 213 IBEX MEDICAL ANALYTICS LTD.: COMPANY OVERVIEW 248
TABLE 214 IBEX MEDICAL ANALYTICS LTD.: PRODUCTS/SERVICES OFFERED 248
TABLE 215 IBEX MEDICAL ANALYTICS LTD.: PRODUCT/SERVICE LAUNCHES/APPROVALS, JANUARY 2021–OCTOBER 2024 249
TABLE 216 IBEX MEDICAL ANALYTICS LTD: DEALS, JANUARY 2021–OCTOBER 2024 250
TABLE 217 MINDPEAK GMBH: COMPANY OVERVIEW 252
TABLE 218 MINDPEAK GMBH: PRODUCTS/SERVICES OFFERED 252
TABLE 219 MINDPEAK GMBH: PRODUCT/SERVICE APPROVALS,
JANUARY 2021–OCTOBER 2024 253
TABLE 220 MINDPEAK GMBH: DEALS, JANUARY 2021–OCTOBER 2024 253
TABLE 221 MINDPEAK GMBH: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024 253
TABLE 222 TRIBUN HEALTH: COMPANY OVERVIEW 254
TABLE 223 TRIBUN HEALTH: PRODUCTS/SERVICES OFFERED 254
TABLE 224 TRIBUN HEALTH: DEALS, JANUARY 2021–OCTOBER 2024 255
TABLE 225 TECHCYTE, INC.: COMPANY OVERVIEW 256
TABLE 226 TECHCYTE, INC.: PRODUCTS/SERVICES OFFERED 256
TABLE 227 TECHCYTE, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021–OCTOBER 2024 257
TABLE 228 TECHCYTE, INC.: DEALS, JANUARY 2021–OCTOBER 2024 257
TABLE 229 TECHCYTE, INC.: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024 257
TABLE 230 DEEP BIO INC.: COMPANY OVERVIEW 258
TABLE 231 DEEP BIO INC.: PRODUCTS/SERVICES OFFERED 258
TABLE 232 DEEP BIO INC.: DEALS, JANUARY 2021–OCTOBER 2024 259
TABLE 233 LUMEA INC.: COMPANY OVERVIEW 260
TABLE 234 LUMEA INC.: PRODUCTS/SERVICES OFFERED 260
TABLE 235 LUMEA INC.: DEALS, JANUARY 2021–OCTOBER 2024 261
TABLE 236 VISIOPHARM: COMPANY OVERVIEW 262
TABLE 237 VISIOPHARM: PRODUCTS/SERVICES OFFERED 262
TABLE 238 VISIOPHARM: PRODUCT LAUNCHES, JANUARY 2021–OCTOBER 2024 263
TABLE 239 VISIOPHARM: EXPANSIONS, JANUARY 2021–OCTOBER 2024 263
TABLE 240 AETHERAI: COMPANY OVERVIEW 265
TABLE 241 AETHERAI: PRODUCTS/SERVICES OFFERED 265
TABLE 242 AETHERAI: DEALS, JANUARY 2021–OCTOBER 2024 265
TABLE 243 AIOSYN: COMPANY OVERVIEW 266
TABLE 244 AIOSYN: PRODUCTS/SERVICES OFFERED 266
TABLE 245 AIOSYN: PRODUCT/SERVICE LAUNCHES, JANUARY 2021–OCTOBER 2024 267
TABLE 246 AIOSYN: DEALS, JANUARY 2021–OCTOBER 2024 267
TABLE 247 AIOSYN: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024 267
TABLE 248 PAIGE AI, INC.: COMPANY OVERVIEW 268
TABLE 249 PAIGE AI, INC.: PRODUCTS/SERVICES OFFERED 268
TABLE 250 PAIGE AI, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS,
JANUARY 2021–OCTOBER 2024 269
TABLE 251 PAIGE AI, INC.: DEALS, JANUARY 2021–OCTOBER 2024 270
TABLE 252 PAIGE AI, INC.: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024 270
TABLE 253 PROSCIA, INC.: COMPANY OVERVIEW 271
TABLE 254 PROSCIA, INC.: PRODUCTS/SERVICES OFFERED 271
TABLE 255 PROSCIA, INC.: PRODUCT/SERVICE LAUNCHES & ENHANCEMENTS,
JANUARY 2021–OCTOBER 2024 272
TABLE 256 PROSCIA, INC.: DEALS, JANUARY 2021–OCTOBER 2024 273
TABLE 257 PROSCIA, INC.: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024 273
TABLE 258 PATHAI, INC.: COMPANY OVERVIEW 274
TABLE 259 PATHAI, INC.: PRODUCTS/SERVICES OFFERED 274
TABLE 260 PATHAI, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS,
JANUARY 2021–OCTOBER 2024 275
TABLE 261 PATHAI, INC.: DEALS, JANUARY 2021–OCTOBER 2024 276
TABLE 262 TEMPUS LABS, INC.: COMPANY OVERVIEW 277
TABLE 263 TEMPUS LABS, INC.: PRODUCTS/SERVICES OFFERED 277
TABLE 264 TEMPUS LABS, INC.: PRODUCT/SERVICE LAUNCHES,
JANUARY 2021–OCTOBER 2024 277
TABLE 265 KONFOONG BIOINFORMATION TECH CO., LTD.: COMPANY OVERVIEW 278
TABLE 266 DOMORE DIAGNOSTICS AS: COMPANY OVERVIEW 278
TABLE 267 VERILY LIFE SCIENCES, LLC: COMPANY OVERVIEW 279
TABLE 268 DEEPPATH: COMPANY OVERVIEW 279
TABLE 269 4D PATH INC.: COMPANY OVERVIEW 280
LIST OF FIGURES
FIGURE 1 RESEARCH DESIGN 31
FIGURE 2 PRIMARY SOURCES 34
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 35
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 36
FIGURE 5 AI IN PATHOLOGY MARKET: REVENUE SHARE ANALYSIS ILLUSTRATION 37
FIGURE 6 BOTTOM-UP APPROACH: END-USER SPENDING ON AI IN PATHOLOGY 38
FIGURE 7 AI IN PATHOLOGY MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024–2029) 39
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 40
FIGURE 9 TOP-DOWN APPROACH 40
FIGURE 10 DATA TRIANGULATION METHODOLOGY 41
FIGURE 11 AI IN PATHOLOGY MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION) 44
FIGURE 12 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2024 VS. 2029 (USD MILLION) 45
FIGURE 13 AI IN PATHOLOGY MARKET, BY USE CASE, 2024 VS. 2029 (USD MILLION) 45
FIGURE 14 AI IN PATHOLOGY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 46
FIGURE 15 AI IN PATHOLOGY MARKET: GEOGRAPHIC SNAPSHOT 47
FIGURE 16 DEVELOPMENT OF CNNS AND AI LEARNING MODELS TO PROPEL MARKET 48
FIGURE 17 NORTH AMERICA TO DOMINATE MARKET DURING FORECAST PERIOD 49
FIGURE 18 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES IN CHINA ACCOUNTED FOR LARGEST MARKET SHARE IN 2023 50
FIGURE 19 US TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 51
FIGURE 20 AI IN PATHOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 52
FIGURE 21 HEALTHCARE BREACHES REPORTED TO US DEPARTMENT OF HEALTH AND
HUMAN SERVICES (SEPTEMBER 2024) 59
FIGURE 22 AI IN PATHOLOGY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 60
FIGURE 23 ECOSYSTEM ANALYSIS 61
FIGURE 24 VALUE CHAIN ANALYSIS 62
FIGURE 25 EUROPE: IVDR TIMELINE 68
FIGURE 26 THERE IS MODERATE-TO-HIGH COMPETITIVE INTENSITY AMONG MARKET PLAYERS 71
FIGURE 27 NUMBER OF PATENTS PUBLISHED, JANUARY 2015−OCTOBER 2024 73
FIGURE 28 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR AI IN PATHOLOGY PATENTS (JANUARY 2015 TO MAY 2024) 74
FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
OF AI IN PATHOLOGY PRODUCTS 75
FIGURE 30 KEY BUYING CRITERIA FOR AI IN PATHOLOGY PRODUCTS 76
FIGURE 31 FUNDING ACTIVITIES IN AI IN PATHOLOGY MARKET 79
FIGURE 32 MARKET POTENTIAL OF AI/GENERATIVE AI IN PATHOLOGY 81
FIGURE 33 NORTH AMERICA: AI IN PATHOLOGY MARKET SNAPSHOT 138
FIGURE 34 ASIA PACIFIC: AI IN PATHOLOGY MARKET SNAPSHOT 168
FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS FOR AI IN PATHOLOGY MARKET, 2019−2023 207
FIGURE 36 AI IN PATHOLOGY MARKET: MARKET SHARE ANALYSIS (2023) 208
FIGURE 37 AI IN PATHOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 211
FIGURE 38 AI IN PATHOLOGY MARKET: COMPANY FOOTPRINT 212
FIGURE 39 AI IN PATHOLOGY MARKET: COMPANY EVALUATION MATRIX
(STARTUPS/SMES), 2023 218
FIGURE 40 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF LIFE SCIENCE ANALYTICS VENDORS 220
FIGURE 41 EV/EBITDA OF KEY VENDORS 220
FIGURE 42 AI IN PATHOLOGY MARKET: BRAND/PRODUCT COMPARISON ANALYSIS 221
FIGURE 43 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2023) 226
FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023) 229
FIGURE 45 HOLOGIC, INC.: COMPANY SNAPSHOT (2023) 233
FIGURE 46 AKOYA BIOSCIENCES, INC.: COMPANY SNAPSHOT (2023) 236
FIGURE 47 AIFORIA TECHNOLOGIES PLC: COMPANY SNAPSHOT (2023) 239
MarketsandMarkets（マーケッツアンドマーケッツ）は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 栄養補助食品用包装市場 – 2030年までの世界予測 2025-04-07
- 産業用ボイラー市場 – 2030年までの世界予測 2025-04-04
- オープンギア用潤滑油市場 – 2030年までの世界予測 2025-04-04
- 建設重機市場 – 2030年までの世界予測 2025-04-03
- 従来の創傷ケア市場 – 2030年までの世界予測 2025-04-02